跳至主要内容
临床试验/NCT00380965
NCT00380965已完成4 期

A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer

NEMA Research, Inc.4 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2006年10月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
23
试验地点
4
主要终点
The Average Pain Score at target site.

研究概览

简要总结

This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.

详细描述

To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain.

This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A pretreatment phase and a treatment phase.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with chemotherapy-induced neuropathic pain.
  • Chronic daily pain present for at least 2 months.
  • On stable analgesic regimen for one month.
  • Baseline pain score greater than 40mm on a VAS.

排除标准

  • Hypersensitivity to compounds in study drug or similar drugs
  • Pregnant or lactating females
  • Drug or alcohol abuse
  • Unstable medical condition

结局指标

主要结局

The Average Pain Score at target site.

次要结局

  • The Pain at Night Score at target site.
  • Patient satisfaction with treatment.
  • Safety will be assessed through the collection of AEs and vital signs.
  • The Worst Pain Score at target site.
  • Quality of Life measures.

研究者

申办方类型
Industry

研究点 (4)

Loading locations...

相似试验